Skip to Main Content

Paper Details

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
Eur J Cancer
38
2021
Author NameAffiliation
Gregory R PondMcMaster University
  • 1 - 1

Datasets

Release 1.2